Terms: = Leukemia AND CD52, CDW52, EDDM5 AND Staging
4 results:
1. Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia.
Huang PY; Best OG; Almazi JG; Belov L; Davis ZA; Majid A; Dyer MJ; Pascovici D; Mulligan SP; Christopherson RI
Leuk Lymphoma; 2014 Sep; 55(9):2085-92. PubMed ID: 24289109
[TBL] [Abstract] [Full Text] [Related]
2. Chronic lymphocytic leukemia: insights from lymph nodes & bone marrow and clinical perspectives.
Jaksić O; Kardum-Skelin I; Jaksić B
Coll Antropol; 2010 Mar; 34(1):309-13. PubMed ID: 20432765
[TBL] [Abstract] [Full Text] [Related]
3. Genetics, gene expression, and targeted therapies in chronic lymphocytic leukemia.
Winkler D; Döhner H; Stilgenbauer S
Curr Drug Targets; 2006 Oct; 7(10):1313-27. PubMed ID: 17073593
[TBL] [Abstract] [Full Text] [Related]
4. Free circulating soluble cd52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-cd52 antibodies.
Albitar M; Do KA; Johnson MM; Giles FJ; Jilani I; O'Brien S; Cortes J; Thomas D; Rassenti LZ; Kipps TJ; Kantarjian HM; Keating M
Cancer; 2004 Sep; 101(5):999-1008. PubMed ID: 15329909
[TBL] [Abstract] [Full Text] [Related]
